China SXT Pharma to establish R&D for advanced TCMP engineering techniques

The Center allows further strengthening R&D capabilities and advances TCMP engineering technologies and is expected to receive additional benefits in marketing

China SXT Pharmaceuticals, Inc., a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements ("TCMHS") announced that it has been granted to establish the Taizhou Research Center for Advanced TCMP Engineering Techniques by the Taizhou Science and Technology Bureau, a department of the Taizhou city government.

The Center, a project founded by the Taizhou Tech Innovation Assembly Program, is supported by the Taizhou government. With the establishment of the Center, the Company is expected to further its lead on research and development of Advanced TCMPs and receive additional benefits when marketing its Advanced TCMP products in the future. 

Mr. Feng Zhou, Chief Executive Officer and Director of China SXT, commented, "Being granted to participate in the Taizhou Tech Innovation Assembly Program is a true testimony to our continuous effort in the research and development of TCMPs. The Center allows us to further strengthen our research and development capabilities and advance our TCMP engineering technologies, which leads us one step closer to achieving our goal of becoming a leading specialty pharmaceutical company in TCMPs."

-----------------------------------------------------------------------
Editor's Note: For any copyright disputes involving the content,
please email: Julia.Zhang@ubmsinoexpo.com to delete.